The adaptor molecules LAT and SLP-76 are specifically targeted by Yersinia to inhibit T cell activation
- PMID: 15699071
- PMCID: PMC2213036
- DOI: 10.1084/jem.20041120
The adaptor molecules LAT and SLP-76 are specifically targeted by Yersinia to inhibit T cell activation
Abstract
T cell responses are critical to the survival of Yersinia-infected animals. Yersinia have the ability to directly suppress T lymphocyte activation through the virulence factor YopH, a tyrosine phosphatase. Using single cell video microscopy and FACS analysis, here we show that even an average of one Yersinia per T cell is sufficient to inhibit or alter T cell responses. This efficient inhibition is traced to specific targeting by YopH of the adaptor proteins, linker for activation of T cells (LAT) and SH2-domain-containing leukocyte protein of 76 kD (SLP-76), which are crucial for T cell antigen receptor (TCR) signaling. A catalytically inactive YopH translocated via the type III secretory pathway from the bacteria into T cells primarily binds to LAT and SLP-76. Furthermore, among the proteins of the TCR signaling pathway, the tyrosine phosphorylation levels of LAT and SLP-76 are the most affected in T cells exposed to low numbers of Yersinia pseudotuberculosis. This is the first example showing that a pathogen targets these adaptor proteins in the TCR signaling pathway, suggesting a novel mechanism by which pathogens may efficiently alter T cell-mediated immune responses.
Figures







Comment in
-
Bacterial toxins and the immune system: show me the in vivo targets.J Exp Med. 2005 Feb 7;201(3):321-3. doi: 10.1084/jem.20050080. J Exp Med. 2005. PMID: 15699067 Free PMC article.
References
-
- Hornef, M.W., M.J. Wick, M. Rhen, and S. Normark. 2002. Bacterial strategies for overcoming host innate and adaptive immune responses. Nat. Immunol. 3:1033–1040. - PubMed
-
- Toivanen, A., K. Granfors, R. Lahesmaa-Rantala, R. Leino, T. Stahlberg, and R. Vuento. 1985. Pathogenesis of Yersinia-triggered reactive arthritis: immunological, microbiological and clinical aspects. Immunol. Rev. 86:47–70. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials